Submitted:
22 September 2025
Posted:
23 September 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Variables and Outcome definition
2.3. Statistical Analysis
3. Results
3.1. Overall Patient Characteristic and Comparison between Hospitalization and Outpatient Groups
3.2. Risk factors for hospitalization in tuberculosis patients
3.3. LASSO Cox regression
3.4. Time-Dependent ROC curve Analysis
4. Discussion
5. Conclusion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
| TB | Tuberculosis |
| ROK | Republic of Korea |
| ICU | Intensive care unit |
| BMI | Body mass index |
| BUN | Blood urea nitrogen |
| CRP | C-reactive protein |
| OOF | Out-of-fold |
| LASSO | Least absolute shrinkage and selection operator |
| Afp-HCC | Alpha-fetoprotein-negative hepatocellular carcinoma |
| CDW | Clinical data warehouse |
| WBC | White blood cell |
| AST | Aspartate-amonitransferase |
| ALT | Alanin-aminotransferase |
| C-index | Concordance index |
| ROC | Receiver operating characteristic |
| AUC | Area under the curve |
| NET | Neutrophil extracellular traps |
References
- Yang, H.; Ruan, X.; Li, W.; Xiong, J.; Zheng, Y. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990–2021: a systematic analysis for the Global Burden of Diseases 2021 study. BMC Public Health 2024, 24, 3111.
- Lee, H.; Kim, J.; Kim, J.; Park, Y.-J.; Jeong, H.; Kim, H.; Shin, J.; Ahn, H.; Lee, E.; Jang, A. Tuberculosis notification status in the Republic of Korea, 2024. 2025.
- Kim, C.W.; Kim, S.H.; Lee, S.N.; Lee, S.J.; Lee, M.K.; Lee, J.H.; Shin, K.C.; Yong, S.J.; Lee, W.Y. Risk factors related with mortality in patient with pulmonary tuberculosis. Tuberc Respir Dis (Seoul) 2012, 73, 38-47.
- Kwon, O.B.; Kim, H.W.; Kim, J.S.; Lee, E.G.; Park, Y.; Jung, S.S.; Kim, J.W.; Oh, J.Y.; Lee, S.H.; Kim, S., et al. Nutrition Status and Comorbidities Are Important Factors Associated With Mortality During Anti-Tuberculosis Treatment. J Korean Med Sci 2025, 40.
- Kim, D.K.; Kim, H.J.; Kwon, S.Y.; Yoon, H.I.; Lee, C.T.; Kim, Y.W.; Chung, H.S.; Han, S.K.; Shim, Y.S.; Lee, J.H. Nutritional deficit as a negative prognostic factor in patients with miliary tuberculosis. Eur Respir J 2008, 32, 1031-1036.
- Carr, B.Z.; Briganti, E.M.; Musemburi, J.; Jenkin, G.A.; Denholm, J.T. Effect of chronic kidney disease on all-cause mortality in tuberculosis disease: an Australian cohort study. BMC Infectious Diseases 2022, 22, 116.
- Pradhan, R.R.; Yadav, A.K. Incidence, Clinical Features, Associated Factors and Outcomes of Intensive Phase Antituberculosis Drug Induced Liver Injury Among Patients With Tuberculosis at a Tertiary Care Hospital in Nepal: A Descriptive Cross-Sectional Study. Health Science Reports 2025, 8, e70686.
- Mishra, S.; Gala, J.; Chacko, J. Factors Affecting Mortality in Critically Ill Patients With Tuberculosis: A Systematic Review and Meta-Analysis. Crit Care Med 2024, 52, e304-e313.
- Tibshirani, R. The lasso method for variable selection in the Cox model. Stat Med 1997, 16, 385-395.
- Liu, G.-M.; Zeng, H.-D.; Zhang, C.-Y.; Xu, J.-W. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell International 2019, 19, 138.
- Li, Y.; Ge, D.; Gu, J.; Xu, F.; Zhu, Q.; Lu, C. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies. BMC Cancer 2019, 19, 886.
- Zhou, D.; Liu, X.; Wang, X.; Yan, F.; Wang, P.; Yan, H.; Jiang, Y.; Yang, Z. A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy. BMC Cancer 2021, 21, 246.
- O'Garra, A.; Redford, P.S.; McNab, F.W.; Bloom, C.I.; Wilkinson, R.J.; Berry, M.P. The immune response in tuberculosis. Annu Rev Immunol 2013, 31, 475-527.
- Yang, C.T.; Cambier, C.J.; Davis, J.M.; Hall, C.J.; Crosier, P.S.; Ramakrishnan, L. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe 2012, 12, 301-312.
- Borkute, R.R.; Woelke, S.; Pei, G.; Dorhoi, A. Neutrophils in Tuberculosis: Cell Biology, Cellular Networking and Multitasking in Host Defense. Int J Mol Sci 2021, 22.
- Muefong, C.N.; Sutherland, J.S. Neutrophils in Tuberculosis-Associated Inflammation and Lung Pathology. Frontiers in Immunology 2020, Volume 11 - 2020.
- de Melo, M.G.M.; Mesquita, E.D.D.; Oliveira, M.M.; da Silva-Monteiro, C.; Silveira, A.K.A.; Malaquias, T.S.; Dutra, T.C.P.; Galliez, R.M.; Kritski, A.L.; Silva, E.C., et al. Imbalance of NET and Alpha-1-Antitrypsin in Tuberculosis Patients Is Related With Hyper Inflammation and Severe Lung Tissue Damage Frontiers in immunology [Online], 2018, p. 3147. PubMed.
- 2024; 18. Korean Guidelines For Tuberculosis Fifth Edition, 2024, Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention.
- Xu, Y.; Wang, X.; Huang, Y.; Ye, D.; Chi, P. A LASSO-based survival prediction model for patients with synchronous colorectal carcinomas based on SEER. Transl Cancer Res 2022, 11, 2795-2809.
- Waldmann, P.; Mészáros, G.; Gredler, B.; Fuerst, C.; Sölkner, J. Evaluation of the lasso and the elastic net in genome-wide association studies. Front Genet 2013, 4, 270.



|
Hospitalization (n=34 ) |
Outpatient (n=83) |
p- value | |
| Age (years) | 71.35±17.45 | 69.82±16.17 | 0.661 |
| Male | 16 (47.06) | 49 (59.04) | 0.237 |
| Total WBC (/μl) | 8530±4854.30 | 6860±2626.01 | 0.083 |
| Neutrophil (/μl) | 6620.11±4446.51 | 4281.86±2339.54 | 0.033 |
| Lymphocyte(/μl) | 1483.77±566.77 | 1749.76±835.58 | 0.077 |
| Hemoglobin (g/dL) | 11.93±1.93 | 12.33±1.96 | 0.345 |
| Platelet (x103/μl) | 280.77±111.77 | 243.16±87.02 | 0.105 |
| Creatinine (mg/dL) | 0.99±0.68 | 0.93±0.52 | 0.686 |
| Albumin (g/dL) | 0.64±34.03 | 3.68±0.63 | 0.129 |
| AST (U/L) | 34.03±39.68 | 40.17±57.85 | 0.530 |
| ALT (U/L) | 19.06±11.56 | 27.89±27.74 | 0.022 |
| Total bilirubin (mg/dL) | 0.66±0.49 | 0.59±0.30 | 0.439 |
| CRP (mg/dL) | 4.19±4.27 | 3.74±3.98 | 0.677 |
| Total cholesterol (mg/dL) | 154.40±40.41 | 152.41±35.71 | 0.815 |
| Univariable | Multivariable | |||
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p- value | |
| Age (years) | 1.010 (0.985-1.030)) | 0.571 | ||
| Male | 0.633 (0.323-1.240) | 0.183 | ||
| Total WBC (/μl) | 1.0014 (1.0005-1.0022) | 0.001 | 0.9996 (0.9992-1.0001) | 0.113 |
| Neutrophil (/μl) | 1.0016 (1.0008 -1.0024) | P<0.001 | 1.6652 (1.0389-2.6691) | 0.034 |
| Lymphocyte (/μl) | 0.9959 (0.9903 -1.0015) | 0.999 | ||
| Hemoglobin (g/dL) | 0.903 (0.740-1.090) | 0.281 | ||
| Platelet (x103/μl) | 1.0381 (1.0018-1.0757) | 0.040 | 1.0016 (0.9975-1.0058) | 0.437 |
| Creatinine (mg/dL) | 1.230 (0.699-2.180) | 0.469 | ||
| Albumin (g/dL) | 0.648 (0.390-1.080) | 0.095 | ||
| AST (U/L) | 0.998 (0.988-1.010) | 0.619 | ||
| ALT (U/L) | 0.978 (0.650-1.010) | 0.137 | ||
| Total bilirubin (mg/dL) | 1.560 (0.620-3.910) | 0.346 | ||
| CRP (mg/dL) | 1.020 (0.929-1.120) | 0.692 | ||
| Total cholesterol (mg/dL) | 1.000 (0.991-1.010) | 0.937 | ||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).